Everolimus has been implicated previously as a drug that can induce cholestasis in humans, which could be attributed to potent inhibition of the human bile salt export pump (BSEP) even when NTCP-mediated bile acid uptake is impaired. The gene discussed is SLC10A1; the disease is cholestasis.